Media Articles Related to Rubramin PC (Cyanocobalamin)
Third Annual EU Device and Diagnostic Regulation Conference, June 12-13, 2014, Brussels
Source: Conferences News From Medical News Today [2014.04.03]
For the third straight year, Q1 Productions will host the EU Device and Diagnostic Regulation Conference, offering attendees an exclusive opportunity to participate in interactive discussions with...
New diagnostic test for bowel diseases
Source: Colorectal Cancer News From Medical News Today [2014.03.31]
A novel method for distinguishing different types of bowel disease using the stool samples of patients has been created by a group of researchers in the UK.
New app turns any smartphone into a portable medical diagnostic device
Source: Urology / Nephrology News From Medical News Today [2014.03.22]
A recently-developed mobile phone application could make monitoring conditions such as diabetes, kidney disease, and urinary tract infections much clearer and easier for both patients and doctors...
New diagnostic, treatment approach for aggressive prostate cancer suggested by cholesterol-metabolism study
Source: Cholesterol News From Medical News Today [2014.03.06]
Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new...
Schizophrenia enters the molecular diagnostics era
Source: Schizophrenia News From Medical News Today [2014.02.13]
With a drop of blood and some laboratory analyses, doctors have been able to tell patients whether they suffer from diabetes or some sort of cancer.
Published Studies Related to Rubramin PC (Cyanocobalamin)
Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. [2009.02.23]
BACKGROUND: Observational epidemiologic studies indicate a direct association between homocysteine concentration in the blood and the risk of age-related macular degeneration (AMD), but randomized trial data to examine the effect of therapy to lower homocysteine levels in AMD are lacking. Our objective was to examine the incidence of AMD in a trial of combined folic acid, pyridoxine hydrochloride (vitamin B(6)), and cyanocobalamin (vitamin B(12)) therapy... CONCLUSIONS: These randomized trial data from a large cohort of women at high risk of cardiovascular disease indicate that daily supplementation with folic acid, pyridoxine, and cyanocobalamin may reduce the risk of AMD.
Comparative effects of hydroxocobalamin and cyanocobalamin on plasma homocysteine concentrations in end-stage renal disease. [2005.10]
End-stage renal disease (ESRD) is associated with marked hyperhomocysteinemia which is only partially corrected by folic acid and pyridoxine supplementation. We and others have reported that various forms of parenteral cobalamin reduce plasma total homocysteine (tHcy) concentrations of patients with ESRD substantially below the lowest levels attainable with folic acid...
Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. [2005.05.23]
BACKGROUND: Supplementation with high doses of oral cobalamin is as effective as cobalamin administered by intramuscular injection to correct plasma markers of vitamin B(12) deficiency, but the effects of lower oral doses of cobalamin on such markers are uncertain... CONCLUSION: The lowest dose of oral cyanocobalamin required to normalize mild vitamin B(12) deficiency is more than 200 times greater than the recommended dietary allowance, which is approximately 3 mug daily.
Clinical Trials Related to Rubramin PC (Cyanocobalamin)
Plasma Holotranscobalamin as Compared to Plasma Cobalamins for Assessment of Vitamin B12 Absorption [Completed]
In the present study the design of the vitamin B12 absorption test, CobaSorb, is further
optimised. We investigate which test – measurement of holotranscobalamin or cobalamins –
could be used for reflection of vitamin B12 absorption. Furthermore, we prolong the duration
of vitamin B12 administration in order to determine the final duration of the vitamin B12
absorption test CobaSorb.
Seventy-eight healthy individuals (age 21-81 years) are treated with three oral doses of 9
microgram cyanocobalamin per day for five successive days. Non-fasting blood samples are
collected on day 1-5 before administration of the first dose of vitamin B12 and on day 8.
Cobalamins and holotranscobalamin are measured on day 1–5 and 8. The performance of the
vitamin B12 absorption test will be evaluated in individuals with borderline or low levels of
holotranscobalamin or cobalamins (below the 75% percentiles) using a change larger than
2CV(day to day) of holotranscobalamin (22%) and cobalamins (12%) to indicate a change caused
by absorption of the administered vitamin B12.
How Many Patients Are in Need of Vitamin B12 Injections? [Recruiting]
The clinical consequences of vitamin B12 deficiency include megaloblastic anemia and
neurological disorders. Therefore, a proper and timely diagnosis and treatment is important.
The use of sensitive biochemical markers such as methylmalonic acid for the diagnosis of
vitamin B12 deficiency have increased since the 1980s. Consequently, the number of
individuals treated with vitamin B12 has increased significantly.
The objective of this project is to study the actual need for vitamin B12 injections in the
group of individuals who have already started treatment. In order to investigate this, the
investigators stop vitamin B12 treatment in this group, and look for signs of vitamin B12
deficiency by monitoring changes in biochemical and hematological markers. Furthermore, they
will test if the individuals are able to absorb a physiological dose of vitamin B12 using a
recently developed absorption test (CobaSorb). If a physiological dose can be absorbed, the
vitamin B12 injections can be replaced with tablets. In the end, the investigators hope to be
able to divide the patients into three groups:
1. need life long injections with vitamin B12,
2. only need supplementations with a small dose of oral vitamin B12, and
3. no need for further vitamin B12 treatment.
The perspective is that the new information from this study might be used for a future
strategy for vitamin B12 treatment.
Can Recombinant Human Intrinsic Factor Be Used for Evaluation of the Vitamin B12 Absorption? [Completed]
Vitamin B12 is an essential nutrient for normal DNA-synthesis and must be supplied by animal
products. Vitamin B12 deficiency may cause anemia and irreverible neurological damage.
Laboratory tests are used for diagnosis of vitamin B12 deficiency, and following the
diagnosis, the cause of the vitamin B12 deficiency has to be clarified. For years a test
called Shilling’s test has been used for evaluation of the vitamin B12 absorption. However,
the Schilling’s test is no longer easy accessible because of increasing difficulties to
obtain the radioactively labeled vitamin B12 requested, and native human intrinsic factor for
Schilling’s test II (absorption of vitamin B12 attached to intrinsic factor) is no longer
available in most countries. Recently, human intrinsic factor unsaturated with vitamin B12
has been expressed in the plant Arabidopsis thaliana. The purpose of this study was to
examine whether recombinant human intrinsic factor is able to promote the uptake of vitamin
B12 in patients with evident vitamin B12 deficiency.
Oral Vitamin B12 Supplementation and Cognitive Performance in Elderly People [Completed]
The purpose of this trial is to study the effects of oral vitamin B12 supplementation and
vitamin B12 combined with folic acid supplementation on cognitive performance for 24 weeks in
elderly people with mild vitamin B12 deficiency.
Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption [Recruiting]
Vitamin B12 is an essential nutrient that the body needs for cells to divide and function
normally. Individuals may develop a deficiency of vitamin B12 by either limiting the amount
in the diet or by decreased vitamin B12 intake into the body (absorption). Keeping adequate
B12 blood levels is important for health. Vitamin B12 deficiency may increase one's risk
for developing anemia and can even lead to neurological problems and paralysis if the
deficiency is severe and lasts a long time. It is very important for doctors to have
accurate tests to determine if people are absorbing vitamin B12 normally so that treatment
can be started before severe clinical problems occur.
The purpose of this research is to provide new information that may help scientists develop
a better method to test for problems with absorbing vitamin B12. In this study, changes in
the amounts of vitamin B12 bound to protein (transcobalamin) in the blood will be measured
after doses of vitamin B12 are taken. If the amounts of this vitamin B12-protein complex
(called holo-transcobalamin) change in response to taking a vitamin B12 supplement in normal
individuals, it may be possible to use this information to develop a new sensitive test to
identify individuals who have problems absorbing vitamin B12. This new vitamin B12
absorption test may be a better clinical test for vitamin B12 absorption than those now
available for doctors to use.